Phase 3 study on previously untreated chronic lymphocytic leukemia showed sustained PFS with venetoclax-obinutuzumab.

The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton ...

Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 ...

Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular ...

This article was published on November 16, 2024, at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by grants ...

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by Amgen. Disclosure forms provided by the authors are available with the ...

No new safety signals were identified. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by Eli Lilly. Disclosure forms ...

In the multicenter, open-label, single-arm MOLTO study (ClinicalTrials.gov Identifier: NCT04082897), researchers treated 28 patients with previously-untreated DLBCL-RT with atezolizumab plus ...